Clinical trial
Cabozantinib in Patients With Locally Advanced or Metastatic Urothelial Cell Carcinoma Who Have Progressed After Cisplatin-based Chemotherapy and Anti-PD-1/PD-L1 Therapy or After Anti-PD-1/PD-L1 Therapy Only.
NCT04066595 is registered in ClinicalTrials.gov with Johannes Gutenberg University Mainz as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Cabozantinib in Patients With Locally Advanced or Metastatic Urothelial Cell Carcinoma Who Have Progressed After Cisplatin-based Chemotherapy and Anti-PD-1/PD-L1 Therapy or After Anti-PD-1/PD-L1 Therapy Only.
- Lead sponsor
- Johannes Gutenberg University Mainz
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- February 10, 2020
- Completion date
- July 1, 2021
- Enrollment
- 7 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
urothelial carcinoma